Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Investor5876on Oct 11, 2024 3:22pm
258 Views
Post# 36263155

Volume

VolumeI'm pleased (relieved) to see the share price hold at a higher level without extreme volumes.

Apart from October 7th, volume of shares traded this week is indicative of real interest in ONC.

I say "real" interest because in the past ONC has had inexplicable massive spikes in volume that were most likely nothing more than ATM activity in its worst form (IMO).

I'm leaning 60/40 that this latest SP increase is due to the market anticipating potential partnership interest vs. pumping up false interest for the ATM (and subsequent financing).

If we have even one day above 5 million shares (on no material news) then the 60/40 will recalibrate to 10/90 immediately. 


<< Previous
Bullboard Posts
Next >>